![Jamie Kasuboski](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jamie Kasuboski
Fondatore presso
Avilar Therapeutics, Inc.
Profilo
Jamie is a Vice President with OMX Ventures.
Prior to OMX Jamie developed deep experience in early-stage Biotech investing and company creation while working on the investment team at RA Capital.
In that role he served on the board of Enara Bio, Avilar Therapeutics, and Endor Therapeutics.
Before joining RA, he was a Director at Boehringer Ingelheim Venture Fund and served as a Board Director of both Tilos Therapeutics (acquired by Merck & Co.) and Rewind Therapeutics.
Education: PhD in Molecular and Cellular Biology from the University of Notre Dame and a BS in Biology with a minor in Chemistry from Hillsdale College
Posizioni attive di Jamie Kasuboski
| Società | Posizione | Inizio |
|---|---|---|
ReAx Biotechnologies
 ReAx Biotechnologies BiotechnologyHealth Technology Engages in drug discovery activities and development of molecular therapies | Direttore/Membro del Consiglio | 01/12/2021 |
Seeker Biologics, Inc.
 Seeker Biologics, Inc. BiotechnologyHealth Technology Develops immunological therapeutic drugs | Direttore/Membro del Consiglio | 01/09/2021 |
Glyphic Biotechnologies Inc
 Glyphic Biotechnologies Inc Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops protein sequencing platform to enable researchers to gain novel insights into biology and disease | Direttore/Membro del Consiglio | 01/04/2021 |
Chicago Biomedical Consortium | Consulente / Consigliere | 01/04/2022 |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops covalent drugs to treat cancer and other autoimmune diseases | Fondatore | 01/11/2019 |
LUMA Group
 LUMA Group Investment ManagersFinance LUMA Group is an active manager. | Investitore di Private Equity | - |
Precedenti posizioni note di Jamie Kasuboski
| Società | Posizione | Fine |
|---|---|---|
Omx Ventures LLC
 Omx Ventures LLC Investment ManagersFinance OMX Ventures invests in companies located across the United States, United Kingdom and Europe. The firm targets companies operating in the fields of therapeutics, Synthetic biology, biotools and diagnostics sectors. It provides financing for seed and early-stage capital requirements and also makes follow- on investments. | Investitore di Private Equity | 01/02/2024 |
Enara Bio Ltd.
 Enara Bio Ltd. BiotechnologyHealth Technology Develops cancer therapies | Direttore/Membro del Consiglio | 01/02/2021 |
ReWind Therapeutics NV
 ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology Develops novel re-myelinating therapies | Direttore/Membro del Consiglio | 01/09/2019 |
| ░░░░░░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Jamie Kasuboski
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
95
Relazioni di 1° grado
13
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 13 |
|---|---|
University of Notre Dame
 University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hillsdale College
 Hillsdale College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boehringer Ingelheim Venture Fund
 Boehringer Ingelheim Venture Fund Investment ManagersFinance Acts as Family of Funds | Finance |
Tilos Therapeutics, Inc.
 Tilos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for cancer, fibrosis and autoimmune disease | Health Technology |
ReWind Therapeutics NV
ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology Develops novel re-myelinating therapies | Health Technology |
Chicago Biomedical Consortium | |
Omx Ventures LLC
Omx Ventures LLC Investment ManagersFinance OMX Ventures invests in companies located across the United States, United Kingdom and Europe. The firm targets companies operating in the fields of therapeutics, Synthetic biology, biotools and diagnostics sectors. It provides financing for seed and early-stage capital requirements and also makes follow- on investments. | Finance |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops covalent drugs to treat cancer and other autoimmune diseases | Commercial Services |
LUMA Group
LUMA Group Investment ManagersFinance LUMA Group is an active manager. | Finance |
Glyphic Biotechnologies Inc
Glyphic Biotechnologies Inc Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops protein sequencing platform to enable researchers to gain novel insights into biology and disease | Commercial Services |
Enara Bio Ltd.
Enara Bio Ltd. BiotechnologyHealth Technology Develops cancer therapies | Health Technology |
ReAx Biotechnologies
ReAx Biotechnologies BiotechnologyHealth Technology Engages in drug discovery activities and development of molecular therapies | Health Technology |
Seeker Biologics, Inc.
Seeker Biologics, Inc. BiotechnologyHealth Technology Develops immunological therapeutic drugs | Health Technology |
